Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491087 | 0.91 | PKM (0.49) | KDM4EALDH1A1PKMMEN1KMT2A | |
| SCHEMBL25857668 | 0.89 | KDM4E (0.42) | KDM4EALDH1A1PKMMEN1KMT2A | |
| SCHEMBL14838548 | 0.76 | GRM2 (0.46) | ALDH1A1KMT2AMAPTGRM2LMNA | |
| SCHEMBL15710231 | 0.76 | MAPK1 (0.44) | ALDH1A1MEN1KMT2AMAPTGRM2 | |
| SCHEMBL26103430 | 0.76 | GRM2 (0.39) | ALDH1A1PKMKMT2AMAPTGRM2 | |
| SCHEMBL6755827 | 0.73 | KDM4E (0.57) | KDM4EALDH1A1PKMMEN1KMT2A | |
| SCHEMBL16502349 | 0.73 | GRM2 (0.37) | ALDH1A1KMT2AMAPTGRM2LMNA | |
| SCHEMBL16815419 | 0.73 | GRM2 (0.37) | ALDH1A1KMT2AMAPTGRM2LMNA | |
| SCHEMBL22338728 | 0.73 | KCNH2 (0.38) | ALDH1A1MAPTGRM2LMNAL3MBTL1 | |
| SCHEMBL24724928 | 0.72 | GRM2 (0.36) | ALDH1A1KMT2AMAPTGRM2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270213-A1 | PI3Ka INHIBITORS | PIKAVATION THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| CN-119654321-A | PI3K alpha inhibitors | 突触活化疗法股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4511373-A1 | PI3K? INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205680-A1 | PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | KDM4E 2955/4885ALDH1A1 3233/4885PKM 2177/4885 |
| US-20250270213-A1 | PI3Ka INHIBITORS | PIK3CA, PIK3C2A, PIK3R5 | KDM4E 2515/4885ALDH1A1 3839/4885PKM 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.